A phase I trial of ZIKV-VLA1601 purified inactivated vaccine candidate against the Zika virus.

Trial Profile

A phase I trial of ZIKV-VLA1601 purified inactivated vaccine candidate against the Zika virus.

Planning
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs ZIKV-VLA1601 (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Valneva
  • Most Recent Events

    • 31 Aug 2017 According to a Valneva media release, Valneva will be responsible for the completion of phase I development of VAL 1601 while Emergent Biosolutions will share the costs.
    • 28 Jul 2017 New trial record
    • 26 Jul 2017 According to an Emergent BioSolutions media release, the companies plan to initiate the Phase 1 trial in late 2017 or early 2018 and data is anticipated within six months from trial initiation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top